OptimizeRx Corp. (NASDAQ:OPRX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

OptimizeRx Corp. (NASDAQ:OPRX) has been assigned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $11.43.

Several equities research analysts have recently commented on the company. Citigroup restated a “market outperform” rating on shares of OptimizeRx in a research note on Friday, August 14th. Stifel Nicolaus set a $12.00 target price on OptimizeRx in a research report on Thursday, August 13th. Wall Street Zen lowered OptimizeRx from a “strong-buy” rating to a “buy” rating in a report on Monday, July 20th. UBS Group set a $11.00 price target on OptimizeRx in a research report on Friday, August 14th. Finally, Weiss Ratings raised OptimizeRx from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, August 25th.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OPRX. Renaissance Technologies LLC increased its stake in shares of OptimizeRx by 633.2% in the first quarter. Renaissance Technologies LLC now owns 216,856 shares of the company’s stock worth $1,362,000 after purchasing an additional 187,278 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in OptimizeRx in the 1st quarter worth $1,185,000. AWM Investment Company Inc. bought a new position in OptimizeRx in the 2nd quarter worth $1,375,000. Next Century Growth Investors LLC increased its stake in OptimizeRx by 139.8% in the 4th quarter. Next Century Growth Investors LLC now owns 505,407 shares of the company’s stock worth $6,196,000 after buying an additional 294,688 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in OptimizeRx by 22.3% during the first quarter. Dimensional Fund Advisors LP now owns 563,570 shares of the company’s stock valued at $3,540,000 after acquiring an additional 102,661 shares during the period. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Stock Performance

OPRX opened at $7.89 on Friday. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 0.14. The company has a market cap of $148.65 million, a price-to-earnings ratio of 34.31 and a beta of 1.09. The company’s 50 day moving average is $7.35 and its 200 day moving average is $6.43. OptimizeRx has a 12-month low of $4.54 and a 12-month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its earnings results on Wednesday, August 12th. The company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.05. OptimizeRx had a net margin of 4.66% and a return on equity of 9.44%. The business had revenue of $20.50 million during the quarter, compared to analysts’ expectations of $20.20 million. On average, equities research analysts predict that OptimizeRx will post 0.51 EPS for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that provides technology and data-driven engagement solutions for life sciences companies, healthcare providers and patients. Its platform is designed to support communication across the healthcare journey, helping pharmaceutical and biotechnology companies connect with clinicians and patients through digital channels.

The company’s solutions include point-of-care messaging, patient savings and financial assistance programs, medication adherence and support services, and analytics and audience-engagement tools.